Motif Bio Plc (LON:MTFB, NASDAQ:MTFB) said two abstracts related to its flagship antibiotic iclaprim will be the focus of poster presentations at the American Society For Microbiology Microbe conference being held in Atlanta from June 7.
The first will outline efficacy data from two phase III clinical trials of the drug in patients with acute bacterial skin and skin structure infections (ABSSSI).
The second will provide a summary from a study in which iclaprim went head to head with Vancomycin, the gold standard treatment for ABSSSI.